Skip to main content
. 2018 Nov 2;12(12):2182–2190. doi: 10.1002/1878-0261.12394

Figure 2.

Figure 2

Effects of NUFS‐sErt in mutant‐EGFR NSCLC cells. (A) Cells were treated with the indicated doses of NUFS‐sErt or erlotinib for 72 h, and cell viability was determined using the MTT assay. Error bars are represented as mean ± SD (= 3). (B) Cells were treated with the indicated doses of NUFS‐sErt or erlotinib for 6 h. Molecules associated with EGFR signaling activity were detected using immunoblotting.